Streptococcus salivarius K12 Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors: A Randomized Controlled Trial The following represents disclosure ...

Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial. This is an ASCO Meeting ...

Risk factors, clinical characteristics, and treatment outcomes for hepatocellular carcinoma in Rwanda. Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo ...

Utilization of PARP inhibitors in the management of ovarian cancer in Nigeria.

Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC). S1507: Phase II study of docetaxel and trametinib ...

This guideline provides recommendations on the management of adults after head and neck cancer (HNC) treatment, focusing on surveillance and screening for recurrence or second primary cancers, ...

OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative ...

EQUITY GI: A prospective study to enhance quality, inclusivity, and trial participation in Black patients with gastrointestinal cancer. Expression of CDH17 in selected gastrointestinal cancer ...

Intravesical gemcitabine and docetaxel in the treatment of BCG-naïve non–muscle invasive urothelial carcinoma of the bladder: Updates from a phase 2 trial.

Prognostic value of month 1 bone marrow and PET MRD status in CAR-T therapy for myeloma. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include a full ...

To provide evidence-based guidance on the use of platelet transfusion in people with cancer. This guideline updates and replaces the previous ASCO platelet transfusion guideline published initially in ...

The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study. This is an ASCO Meeting ...